miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 23, 2026

AS-i Harju Elekter Group majandustulemused, 1-6/2026

View original at globenewswire.com
“Ärikasum enne kulumit (EBITDA) 2 266 4 658 -51,4% 3 905 8 523 -54,2%”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Estonian local distribution grid operator has reduced its investment volumes, weighing on the local market

    60% confidence
  • Q2 and H1 2026 results fell significantly short of both revenue and profit targets due to lower-than-expected sales volume and part of revenue shifting to future periods

    60% confidence
  • Ongoing preparations and a growing order book create the conditions for servicing larger project volumes and for revenue and profitability growth in future years

    60% confidence
  • 2026 is considered a transition year during which the company prepares for the next high-activity periods, with a stronger order book for H2 than H1

    60% confidence
  • In Sweden, long-execution-time projects make up a significant share of the order book, with realization extending into 2028

    60% confidence

Data points we hold from this source

Harju Elekter Group · net income0.272 USD
Harju Elekter Group · labor costs21.4 USD
Harju Elekter Group · margin12.2 percent
Harju Elekter Group · long term financial investments27.223 USD
Harju Elekter Group · labor cost ratio27.7 percent
Harju Elekter Group · capital expenditure3.9 USD
Harju Elekter Group · admin expenses5.627 USD
Harju Elekter Group · admin expense ratio7.3 percent
Harju Elekter Group · employee wage costs16.7 USD
Harju Elekter Group · ebit margin2.6 percent
Harju Elekter Group · debt35.467 USD
Harju Elekter Group · inventory20.456 USD
Harju Elekter Group · equity95.155 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com